EC Number   |
Inhibitors |
Structure  |
|---|
   2.3.2.23 | eupalinolide B |
Kd value 0.00925 mM. UBE2D3 is modified by EB in residue Cys85, the presence of eupalinolide B enhances the thermal stabilization of UBE2D3. Eupanolide B effectively inhibits the activity of UBE2D3 and prevents the degradation of IkappaBalpha and the activation of NF-kappaB |
   |
| 2.3.2.23 | 5-[(piperidin-1-yl)methyl]pyrazolo[1,5-a]pyrimidin-7(4H)-one |
- |
|
| 2.3.2.23 | 5-benzylpyrazolo[1,5-a]pyrimidin-7(4H)-one |
- |
|
| 2.3.2.23 | 5-([4-[2-(thiophen-2-yl)ethyl]piperazin-1-yl]methyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one |
- |
|
| 2.3.2.23 | 5-([4-[(thiophen-2-yl)acetyl]piperazin-1-yl]methyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one |
- |
|
| 2.3.2.23 | 2alpha,6alpha-diacetoxy-4beta-hydroxy-11(13)-pseudoguaien-12,8alpha-olide |
inhibitor directly binds to UbcH5c protein and inhibits cell viability and colony formation, induces apoptosis, and suppresses migration and invasion of pancreatic cancer cells in vitro. The compound inhibits UbcH5c-mediated IkappaBalpha degradation and NF-kappaB activation. The compound suppresses the tumor growth and metastasis in two orthotopic pancreatic tumor mouse models |
|
| 2.3.2.23 | CC0651 |
a small-molecule inhibitor that selectively inhibits Ube2R1, the specialized E2 for SCF E3 ligases, which builds K48-linked polyUb chains on its targets for proteasomal degradation. In a co-crystal structure of Ube2R1, Ub, and CC0651, the inhibitor is sandwiched between the E2 and Ub |
|
| 2.3.2.23 | CC0651 |
- |
|
| 2.3.2.23 | 5,6-dibenzo[c,e][1,2]thiazine-5,5(6H)-dione |
- |
|
| 2.3.2.23 | [1,1'-biphenyl]-2-sulfonamide |
- |
|
